This World Diabetes Day, join the Empower Symposium! A special educational event focused on advancing holistic and personalized diabetes care. Join leading experts as they share insights that combine science, empathy, and innovation to redefine patient outcomes in Type 2 Diabetes Mellitus.

Dr. Banshi Saboo, Chief Diabetologist & Chairman of Dia Care, Ahmedabad, will present the Holistic CRM Approach — a Diabetes India accredited module highlighting integrated patient management strategies. Dr. Sanjay Kalra, Consultant & Head Endocrinologist at Bharti Research Institute of Diabetes & Endocrinology, Karnal, will follow with Personalized Care in T2DM: State of the Art, exploring individualized treatment approaches with cardiovascular focus. The session concludes with a live panel discussion and audience Q&A.

*A certificate will be provided to the attendees who attend the Diabetes India accredited session on Holistic CRM Approach by Dr. Banshi Saboo.

World Diabetes Day

Step into the ultimate medical challenge – the Pfizer Wizards of Medicine Grand Finale! This is the pinnacle of medical knowledge, a comprehensive showdown that will test the absolute limits of your diagnostic skills and clinical reasoning. Navigate through complex medical scenarios that span multiple disciplines, solve intricate puzzles, and prove your mastery across the vast landscape of healthcare. Only the most exceptional medical minds will rise to the top in this ultimate test of medical expertise. Are you ready to become a true Wizard of Medicine?

Pfizer Wizards of Medicine - Grand Finale

Join us for an insightful panel discussion on "Lung in Diabetes," where leading experts will delve into the complex relationship between lung health and diabetes management. Our distinguished speakers will share their knowledge on respiratory complications associated with diabetes, including asthma and COPD, and discuss the impact of glycemic control on lung function. The session will also cover risk assessment strategies, preventive measures, and the latest treatment options available for patients. This is an invaluable opportunity for healthcare professionals to enhance their understanding of how to optimize lung health in individuals with diabetes and stay informed on current best practices. Don't miss this chance to engage with experts and deepen your clinical expertise!

Panel Discussion on Diabetes Lung

Conclude the conference on a high note with an enlightening keynote talk that draws on our recognised expert's broad expertise in diabetes treatment. This session will provide a comprehensive summary of key takeaways, emerging trends, and future directions in diabetes management discussed throughout the conference. Join us for this closing keynote to gain valuable perspectives that will leave you inspired and well-informed, fostering a deeper understanding of the evolving landscape of diabetes care and its potential impact on patients' lives.

Concluding keynote

RCP Diabetology Day-5

Engage in a thought-provoking panel discussion with best experts in the industry, moderated by Dr. Ambrish Mittal, as they examine the controversial status of Modern Sulfonylureas in diabetes treatment. In this session, the panelists will critically evaluate the benefits and risks associated with Modern Sulfonylureas, challenging misconceptions and addressing concerns. Join us for a balanced and insightful conversation that aims to shed light on the role and safety of Modern Sulfonylureas in contemporary diabetes management.

Panel: Modern Sulfonylureas: Dangerous or Wrongly Accused?

RCP Diabetology Day-4

Delve into the world of diabetes treatment innovation with leading diabetology expert and grab latest insights on Imeglimin, a dual-action novel agent for Type 2 Diabetes Mellitus (T2DM). In this session, you'll gain insights into the Imeglimin's mechanism of action at a cellular and molecular level, clinical efficacy, and potential advantages of Imeglimin in managing T2DM. Join us for a comprehensive overview of this promising therapeutic option that may shape the future of diabetes care.

Imeglimin - The Dual Action Novel Agent for T2DM

The traditional medicines used to treat type 2 diabetes usually lose efficacy over time, resulting in insufficient glycemic control and side consequences. As a result, there is a need for alternative therapies that can overcome the limits of traditional anti-diabetic medicines. Gliptins, which have become a focus of significant research, present an alternative therapy method for people with type 2 diabetes. Gliptins improve glycemic control significantly and are well tolerated, particularly in terms of weight change and hypoglycemia. In this session, the panel will critically evaluate the efficacy, safety, and practical applications of Gliptins in contemporary diabetes care, offering insights to clarify their role in clinical practice.

Panel: A Deep Dive into Gliptins - clinical gem or more hype?

RCP Diabetology Day-3

Obesity and type 2 diabetes mellitus (T2DM) are inextricably connected and are becoming more common worldwide. Both chronic illnesses have a multisystem impact and are linked to increased mortality and cardiovascular risk. Dive into a transformative perspective on Type 2 Diabetes management on  "Obesity - A New Nonglycemic Standard." This session will explore the evolving understanding of obesity as a central factor in the management of Type 2 Diabetes, going beyond traditional glycemic control. Join us for an eye-opening discussion on the role of obesity in diabetes and how it is reshaping the approach to treatment, offering new insights into improved patient outcomes and holistic care.

Obesity - A New Nonglycemic Standard In Type 2 Diabetes Management

RCP Diabetology Day-2

RCP Diabetology Day-1

Participate in an engaging discussion with leading industry experts as they analyze how the management of diabetes is changing from a glucocentric strategy to one that focuses on vascular protection. Discover the significance of this evolution, including novel therapies and lifestyle modifications, and gain insights into how this shift is transforming diabetes care, ultimately enhancing patient well-being.

Changing approach of DM Management: Glucocentric to Vascular Protection

Gear up for yet another edge-of-the seat medical quiz exclusively on Medflix! In the spirit of the upcoming Diabetes India 2023 conference, join in for a quiz like none other. Test your understanding of diabetes while competing with other doctors for exciting prizes. RSVP right away and bring your A-game.

Diabetes India Quiz

The incidence of obesity and diabetes, also known as the 'twin epidemics', is a rising global issue, particularly in developed nations. Therefore, cutting-edge therapeutic modalities are required. As the only dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist, tirzepatide, also referred to as a 'twincretin', can significantly lower glycemic levels, improve insulin sensitivity, as well as reduce body weight by more than 20% and improve lipid metabolism. On the other hand, we have the USFDA and the EMA approved Semaglutide, a novel second-generation long-acting GLP-1RA for once-weekly subcutaneous administration, as an adjunct to diet and exercise in individuals with type 2 diabetes that is not well controlled. Join us LIVE as renowned endocrinologists Dr. Om Lakhani and Dr. Mayur Agrawal square off to discuss the benefits and drawbacks of each treatment.

Tirzepatide vs Semaglutide in Patients with Type 2 Diabetes

Dr. Om Lakhani: GLP1a are the most proven therapy in such a high risk patient in such a scenario 
Dr. Pankaj Agarwal: DDP4 i are safer, oral, inexpensive and better alternative in such patients. 
Dr. Banshi Saboo: AGI/ Meglinitide analogue are safer bet in view of CKD

CAD- DIABETES- CKD - GLP1a /DPP4/AGI

India is home to 77 million diabetics, second highest in the world. Given these figures, there are a slew of novel anti-diabetic drug combinations hitting the market every year. Join us as we learn about these new drugs and their efficacy in diabetes treatment with Dr. Banshi Saboo.

Newer Anti-Diabetics

As per CDC, case surveillance data reported through April 2020 indicated that COVID-19 patients with underlying conditions, such as diabetes, were six times more likely to be hospitalized and twelve times likelier to die. This makes learning best practises very important for doctors to manage diabetes effectively in Covid-19 and Covid-19 in diabetic individuals.

Managing Diabetes in Patients with COVID-19

Chief Diabetologist & Chairman of Diabetes Care & Hormone Clinic at Ahmedabad 

Dr. Banshi Saboo

29

13k

344.4k

4.5

Sessions Taken

1.6k

4.8

1.5k

4.6

9

0

781

4.6

0

0

778

4.7

0

0

781

4.7

617

5

0

0

798

5

0

0

0

0

1.4k

0

2k

4.5

993

4.4

1.2k

4.6

2.6k

4.7

410

3.5